Insider Transactions in Q1 2021 at Prometheus Biosciences, Inc. (RXDX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 16
2021
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
375,000
+14.43%
|
$7,125,000
$19.0 P/Share
|
|
Mar 16
2021
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
1,848,022
+50.0%
|
-
|
|
Mar 16
2021
|
Point72 Biotech Private Investments, LLC |
BUY
Open market or private purchase
|
Indirect |
800,000
+23.2%
|
$15,200,000
$19.0 P/Share
|
|
Mar 16
2021
|
Point72 Biotech Private Investments, LLC |
BUY
Conversion of derivative security
|
Indirect |
1,848,024
+43.49%
|
-
|
|
Mar 16
2021
|
Helen C. Adams Director |
BUY
Open market or private purchase
|
Direct |
500
+50.0%
|
$9,500
$19.0 P/Share
|
|
Mar 16
2021
|
Joseph C Papa Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$285,000
$19.0 P/Share
|
|
Mar 16
2021
|
Mark Stenhouse Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
14,000
+50.0%
|
$266,000
$19.0 P/Share
|
|
Mar 16
2021
|
Tadataka Yamada Director |
BUY
Conversion of derivative security
|
Direct |
13,333
+50.0%
|
-
|
|
Mar 16
2021
|
Sinai Medical Center Cedars > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,416,008
+19.92%
|
-
|
|
Mar 16
2021
|
Rtw Investments, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,464,031
+33.3%
|
-
|
|
Mar 16
2021
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
800,000
+50.0%
|
$15,200,000
$19.0 P/Share
|
|
Mar 16
2021
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
850,000
+20.41%
|
$16,150,000
$19.0 P/Share
|
|
Mar 16
2021
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,464,032
+43.49%
|
-
|